Combination Drug Study for KRAS G12C Colorectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests three drugs (adagrasib, cetuximab, cemiplimab) together for colorectal cancer with a KRAS G12C mutation. The goal is to see if this combination shrinks tumors or slows cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer has a specific change called KRAS G12C and has spread or can’t be removed with surgery.
- You’ve had at least one type of chemotherapy that no longer works or you couldn’t tolerate.
- You have not had previous treatment with a PD-1, CTLA-4, or KRAS G12C inhibitor.
- You’re willing to have two tumor biopsies (one before and one during treatment).
- You are able to take pills by mouth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (sotorasib, panitumumab, and FOLFIRI) against the standard treatment for colorectal cancer that has spread. It's for people whose tumor has a specific KRAS G12C mutation and who have not had chemotherapy before for advanced disease.
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
This trial tests a combination of two targeted drugs (panitumumab and sotorasib) with a common IV chemo (5-fluorouracil) as a first treatment for people with a specific type of advanced colorectal cancer who cannot tolerate stronger chemo. It offers a gentler option that may be more effective than standard care.
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.